Sinovac Biotech Co., Ltd

Company Description

Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuit to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine. Sinovac has a robust pipeline of new vaccine products under development. The Company is currently developing vaccines for Enterovirus 71 (EV 71), Pneumococcal Conjugate Vaccine, Hib, and Meningitis. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for an independently developed inactivated animal rabies vaccine.

Company Information

  • Contact Person:Mr. Kevin Chang
  • Department:Marketing
  • Telephone:
  • Fax:
  • Zip:100085
  • Business Type:Manufacturing
  • Year Established:2001
  • Number Of Employees:100+
  • Trade Capacity:Export Percentage:
  • Certificates:GMP, CPP, FSC
  • Legal Representative / CEO:Kevin Chang
  • Main Products:Manufacturer Of Hepatitis A Vaccine, Influenza Vaccine
  • Address:Shangdi West, Beijing, Beijing, China
  • Main Markets:Africa,Asia,America,East Europe,Middle East,Worldw
  • Website:Visit website

Product

  • Anflue®-Inactivated Influenza Vaccine (Split Virion)
  • Healive® - Inactivated Hepatitis A Vaccine
Countries   China   India   Indonesia   Malaysia   Pakistan   Turkey   United Kingdom   United States   All Countries